930 related articles for article (PubMed ID: 29739902)
1. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
2. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
3. Full-Length Isoforms of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Accumulate in the Cytoplasm of Cells Undergoing the Lytic Cycle of Replication.
Garrigues HJ; Howard K; Barcy S; Ikoma M; Moses AV; Deutsch GH; Wu D; Ueda K; Rose TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978712
[TBL] [Abstract][Full Text] [Related]
4. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.
Kim YJ; Kim Y; Kumar A; Kim CW; Toth Z; Cho NH; Lee HR
PLoS Pathog; 2021 Jan; 17(1):e1009179. PubMed ID: 33471866
[TBL] [Abstract][Full Text] [Related]
6. Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.
Mohanty S; Kumar A; Das P; Sahu SK; Choudhuri T
Apoptosis; 2017 Sep; 22(9):1098-1115. PubMed ID: 28653223
[TBL] [Abstract][Full Text] [Related]
7. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
Watanabe T; Fujimuro M
Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
9. ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
Wood JJ; Boyne JR; Paulus C; Jackson BR; Nevels MM; Whitehouse A; Hughes DJ
J Virol; 2016 Oct; 90(20):9543-55. PubMed ID: 27512077
[TBL] [Abstract][Full Text] [Related]
10. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
12. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
Smith CG; Kharkwal H; Wilson DW
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
[TBL] [Abstract][Full Text] [Related]
13. Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin.
Lu J; Jha HC; Verma SC; Sun Z; Banerjee S; Dzeng R; Robertson ES
J Virol; 2014 Apr; 88(8):4204-17. PubMed ID: 24478433
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.
Zhang YJ; Wang KY; Stein DA; Patel D; Watkins R; Moulton HM; Iversen PL; Matson DO
Antiviral Res; 2007 Jan; 73(1):12-23. PubMed ID: 16842866
[TBL] [Abstract][Full Text] [Related]
15. Genipin Enhances Kaposi's Sarcoma-Associated Herpesvirus Genome Maintenance.
Cho M; Jung SW; Lee S; Son K; Park GH; Jung JW; Shin YS; Seo T; Hyosun Cho ; Kang H
PLoS One; 2016; 11(10):e0163693. PubMed ID: 27736870
[TBL] [Abstract][Full Text] [Related]
16. Regulation of KSHV Latency and Lytic Reactivation.
Broussard G; Damania B
Viruses; 2020 Sep; 12(9):. PubMed ID: 32957532
[TBL] [Abstract][Full Text] [Related]
17. KSHV Genome Replication and Maintenance in Latency.
Ueda K
Adv Exp Med Biol; 2018; 1045():299-320. PubMed ID: 29896673
[TBL] [Abstract][Full Text] [Related]
18. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
J Virol; 2017 May; 91(10):. PubMed ID: 28275189
[TBL] [Abstract][Full Text] [Related]
19. Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency.
Mariggiò G; Koch S; Zhang G; Weidner-Glunde M; Rückert J; Kati S; Santag S; Schulz TF
PLoS Pathog; 2017 Apr; 13(4):e1006335. PubMed ID: 28430817
[TBL] [Abstract][Full Text] [Related]
20. Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
Tso FY; West JT; Wood C
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
